More articles from Volume 43, Issue 1, 2014
PROGNOSTIČKI ZNAČAJ GLEASON SCORE-A 7 (3+4) I GLEASON SCORE-A 7 (4+3) U ADENOKARCINOMU PROSTATE U ODNOSU NA KLINIČKI STADIJUM, TKIVNI ANDROGEN STATUS I STEPEN NEUROENDOKRINE DIFERENCIJACIJE
KLINIČKE MANIFESTACIJE OSTEOARTRITISA KOLENIH ZGLOBOVA
DNA identification of war and mass catastrophies victims
Electrocardiography changes in patients with acute myocardial infarction in late hospital phase
SINDROM OPSTRUKCIONE APNEJE U SPAVANJU KOD DECE
PROGNOSTIČKI ZNAČAJ GLEASON SCORE-A 7 (3+4) I GLEASON SCORE-A 7 (4+3) U ADENOKARCINOMU PROSTATE U ODNOSU NA KLINIČKI STADIJUM, TKIVNI ANDROGEN STATUS I STEPEN NEUROENDOKRINE DIFERENCIJACIJE
,
M. Mijovic
,
D. Vukicevic
,
B. Djerkovic
,
V. Nedeljkovic
L. Vitkovic
Abstract
Keywords
References
1.
Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, Forti G, et al. Androgen receptor and prostate cancer invasion. Int J Androl. 2003;(1):21–5.
2.
Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M, et al. Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids. 2008;(9–10):1030–7.
3.
Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol. 2001;(Suppl 2):141-S144.
4.
Cerović S, Brajusković G, Maletić V, Mićić V, S. Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl. 2004;(5):513–8.
5.
Chan T, Partin A, Walsh P, Epstein J. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000;730–4.
6.
Cohen M, Arber D, Coffield K, Keegan G, Mcclintock J, Vo S. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer. 1994;(7):1899–903.
7.
Cohen R, Glezerson G, Haffejee Z. Neuroendocrine cells-a new prognostic parameter in prostate cancer. Br J Urol. 1991;258–62.
8.
Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004;(4):265–71.
9.
Eble J, Epstein J. Stage A carcinoma of the prostate. 1990;61–82.
10.
Epstein J, Jang X. 2002;
11.
Feldman B, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;34–45.
12.
Gleason D. Histologic grading of prostate cancer: a perspective. Hum Path. 1992;273–9.
13.
Gleason D. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;125–8.
14.
Greene D, Wheeler T, Egawa S, Dunn J, Scardino P. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol. 1991;1069–76.
15.
Grossfeld G, Latini D, Lubeck D, Mehta S, Carroll P. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;(1):157–63.
16.
Hammad A, Farhat A, Nuzhat F, Mohammad I, Shahid P. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 2008;21.
17.
Hansson J, Abrahamsson P. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol. 2001;(Suppl 2):145-S152.
18.
Haukaas S, Halvorsen O, Daehlin L, Hostmark J, Akslen L. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int. 2006;(1):51–5.
19.
Heinlein C, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;(2):276–308.
20.
Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004;(5):586–92.
21.
Horiguchi A, Nakashima J, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate. 2003;(1):23–9.
22.
Humphrey P. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;(3):292–306.
23.
Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002;512–5.
24.
Rosai J, M. Ackerman’s Surgical Pathology, eight edition. 1996;1221–56.
25.
Khoddami S, Shariat S, Lotan Y. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int. 2004;42–6.
26.
Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. International journal of urology : official journal of the Japanese Urological Association. 2009;(1):37–44.
27.
Krijnen J, Bogdanowicz J, Seldenrijk C, Mulder P, Van Der Kwast T. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol. 1997;171–4.
28.
Lau W, Blute M, Bostwick D, Weaver A, Sebo T, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001;1692–7.
29.
Leong A, Cooper K, Leong F. 1999;
30.
Lilleby W, Paus E, Skovlund E, Fossa S. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate. 2001;126–33.
31.
Originalni Radovi.
32.
Makarov D, Sanderson H, Partin A. Gleason score 7 prostate cancer on needle biopsy: Is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol. 2002;2440–2.
33.
Mijović M. Fokalna neuroendokrina diferencijacija adenokarcinoma prostate u korelaciji sa histološkim gradusom, kliničkim stadijumom i preoperativnim vrednostima serumskog prostata specifičnog antigena, doktorska disertacija. 2010;
34.
Murphy G, Busch C, Abrahamsson P, Epstein J, Mcneal J, Miller G, et al. Histopathology of localized prostate cancer. Scand J Urol Nephrol Suppl. :7–42.
35.
Nikolić J, Mićić S. Tumori urogenitalnih organa. 2005;3–140.
36.
Dowd G, Veltri R, Miller C, Strum M, S. The Gleason score: a significant biologic manifestation of prostate cancer agressiveness on biopsy. PCRInsights. 2001;
37.
Ou Y, Chen J, Yang C, Cheng C, Ho H, Kao Y, et al. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer. Jpn J Clin Oncol. 2002;(5):172–6.
38.
Parkin D. Global cancer statistics in the year 2000. Lancet Oncol. 2001;533–43.
39.
Rasiah K, Stricker P, Haynes A. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer. 2003;2560–2256.
40.
Rubin M, Bismar T, Curtis S, Montie J. Prostate needle biopsy reporting. Am J Surg Pathol. 2004;(7):946–52.
41.
Sakr W, Tefilli M, Grignon D, Banerjee M, Dey J, Gheiler E, et al. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology. 2000;730–4.
42.
Francisco S, Regan I, Olumi M, Dewolf A, W. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol. 2004;(4):1492–9.
43.
Sebo T, Bock B, Cheville J, Lohse C, Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;(1):174–8.
44.
Steinberg G, Carter B, Beaty T, Childs B, Walsh P. Family history and the risk of prostate cancer. Prostate. 1990;337–47.
45.
Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocrine-Related Cancer. 2003;(2):209–16.
46.
Taplin M, Balk S. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004;(3):483–90.
47.
Tefilli M, Gheiler E, Tiguert R, Sakr W, Grignon D, Banerjee M, et al. Should Gleason score 7 prostate cancer be considered a unique grade category? Urology. 1999;372–7.
48.
Wright M, Tsai M, Aebersold R. Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells. Molecular Endocrinology. 2003;(9):1726–37.
49.
Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Translational Res. 2009;(2):148–62.
50.
Young R, Srigley J, Amin M, Ulbright T, Cubilla A. Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra and Penis. AFIP. 2000;
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
